financingSpexis AG bags money for pivotal Phase III...Swiss Spexis AG has announced a US$2.5m capital commitment to fund a two-part pivotal Phase III study to get market approval for its inhaled cystic fibrosis antibiotic colistimethate sodium. more ➔
M&ANovo Nordisk takes over Inversago Pharma I...With a US$1bn acquisition of Canadian Inversago Pharma, Novo Nordisk A/S fiights to maintain its dominant position in the booming weight loss drug market. more ➔
CGTPromising viral gene therapy for genetic k...British researchers have proven that a new gene can prevent progression of hereditary kidney damage in mice. more ➔
DealAlianza Team invests in microbial oil make...Lipid, nutrition and frozen bakery specialist Allianza Team puts £900,500 into pre-Series A financing of microbial palm oil producer Clean Food Group Ltd. more ➔
studyMore marine plastics than expectedA Dutch-German team of researchers has found out that the amount of not degradable plastics is lower than estimated but that they persist for longer than previously assumed. more ➔
CRo=Sygnature Discovery Ltd acquires leading C... British drug discovery specialist Sygnature Discovery Ltd has taken over Canadian NuChem Sciences Inc., one of North Americas largest discovery CROs more ➔
ScienceEnzyme foams morer active and stableResearchers at the Karlsruhe Institute of Technology (KIT) have transformed enzymes into a new form: as foams, the biocatalysts prove to be extremely stable and active. more ➔
FundingBavarian Nordic A/S bags US$120m for small...Bavarian Nordic A/S will get US$120m from a contract for the manufacturing of smallpox and mpox vaccine from the US government. more ➔
FundingPureTech Health gets US$11.4m to advance L...LSE-listed PureTech Health plc hat been granted p to US$11.4m from U.S. Department of Defense to advance LYT-300 to treat Fragile X-associated tremor/ataxia syndrome. more ➔
MSNeuraxpharm pays US$650m for MS drug comme...TG Therapeutics will receive US$140m upfront from German Neuraxpharm for Ex-US commercialisation rights of its deglycosylated anti-CD20 antibody ublituximab-xiiy. more ➔
